

Javier Hortal  
Maddalena Giannella  
Maria Jesús Pérez  
José Maria Barrio  
Manuel Desco  
Emilio Bouza  
Patricia Muñoz

## Incidence and risk factors for ventilator-associated pneumonia after major heart surgery

Received: 14 September 2008  
Accepted: 6 March 2009  
Published online: 26 June 2009  
© Springer-Verlag 2009

This article is discussed in the editorial available at:  
doi:[10.1007/s00134-009-1522-4](https://doi.org/10.1007/s00134-009-1522-4).

J. Hortal · M. J. Pérez · J. M. Barrio  
Department of Anesthesia, Hospital General Universitario Gregorio Marañón, Madrid, Spain

M. Giannella · E. Bouza · P. Muñoz (✉)  
Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain  
e-mail: [pMunoz@micro.hggm.es](mailto:pMunoz@micro.hggm.es)  
Tel.: +34-91-5868453  
Fax: +34-91-5044906

M. Desco  
Department of Experimental Medicine, Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46, 28007 Madrid, Spain

E. Bouza · P. Muñoz  
CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain

**Abstract Purpose:** Major heart surgery (MHS) patients are a particularly high-risk population for nosocomial infections. Our objective was to identify risk factors for ventilator-associated pneumonia (VAP) in patients undergoing MHS. **Methods:** Prospective study including 1,844 patients operated from 2003 to 2006. **Results:** Overall 106 patients (140 episodes) developed one or more episodes of VAP (5.7%, 22.2 episodes per 1,000 days of mechanical ventilation). VAP incidence was 45.9% in those patients requiring more than 48 h of MV. Enterobacteriaceae (32.8%), *Pseudomonas aeruginosa* (28.6%) and *Staphylococcus aureus* (27.1%, of which 65.8% were methicillin resistant) were the principal microorganisms causing VAP. The independent risk factors for VAP were: age >70,

perioperative transfusions, days of mechanical ventilation, reintubation, previous cardiac surgery, emergent surgery and intraoperative inotropic support. Median length of stay in the ICU for patients who developed VAP or not was, respectively, 25.5 versus 3 days ( $P < 0.001$ ), and mortality was, respectively, 45.7 versus 2.8% in both populations ( $P < 0.001$ ). We developed a predictive preoperative score with a sensitivity of 93% and a specificity of 40%.

**Conclusions:** VAP is common in patients undergoing MHS that require more than 48 h of MV. In that “high-risk” population, innovative preventive measures should be developed and applied.

**Keywords** Ventilator-associated pneumonia · Heart surgery · Nosocomial infection · Nosocomial pneumonia · Risk factors for ICU nosocomial infection

### Introduction

Ventilator-associated pneumonia (VAP) is the most frequent intensive care unit (ICU) acquired infection among patients receiving mechanical ventilation (MV) and is associated with prolonged hospitalization [1–3], increased health care costs [4], and a 15–45% attributable mortality [5, 6].

Patients undergoing major heart surgery (MHS) are a particularly high-risk population for nosocomial infections

during the postoperative period with a high incidence and related mortality [7–11]. However, information regarding the risk factors and outcome of VAP in this setting is scarcely available [12] and needs to be permanently updated.

We carried out a prospective study of VAP in patients undergoing MHS in our institution during a 4-year period in order to assess the differential characteristics of patients who develop VAP and to identify risk factors

amenable to intervention. Some of the results of this study were presented as an abstract at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

## Materials and methods

### Study design

All patients who were admitted to the heart surgery ICU after MHS at our institution [procedures that require extracorporeal circulation (ECC) or surgical revascularizations without ECC] between January 2003 and December 2006 and who survived for at least 48 h were included in the study. All patients were prospectively followed by an infectious diseases (ID) physician who recorded clinical data on a pre-established form and collaborated in the management of infections.

We analyzed the incidence of VAP, its etiology, risk factors, and impact on clinical outcome. Patients were followed up until death or ICU discharge. Informed consent was not required as confidentiality was guaranteed, and no interventions were performed.

### Setting

Our hospital is a 1,750-bed tertiary referral general teaching institution, attending a population of approximately 750,000 inhabitants, with a very active program of MHS that includes heart transplantation.

The heart surgery ICU is a separate unit of 16 beds exclusively for patients who undergo MHS. During the study period, there were no major outbreaks of nosocomial respiratory pathogens in this unit. Our practices for respiratory care include: patient placement in an upright position and perioperative rinsing with chlorhexidine gluconate. Prompt extubation was intended, and 'breath spontaneously trial' (SBT) was performed daily. Patients intubated for >2 weeks underwent tracheostomy [13]. Sedative protocol was: remifentanyl plus propofol and switching to morphine if the patient required sedation over 7 days. Nurses adjusted the dosage and rate of infusion to achieve a Ramsay score of 3 or 4 on the sedation scale. Daily interruption of the sedative infusion was performed as described by Kress et al. [14].

### Clinical protocol

Clinical data were recorded according to a pre-established protocol, and no systematic surveillance of respiratory tract cultures were performed because they were not

useful to predict pneumonia in a previous study in our ICU [12].

Pre-surgical, surgical, and post-surgical characteristics were recorded according to a pre-established protocol. The surgical risk was evaluated by the European system for cardiac operative risk evaluation (EuroSCORE) [15]. Antimicrobial prophylaxis for surgery consisted of 2 g of cefazolin given before surgery and every 8 h thereafter, for a total of three doses (allergic patients received vancomycin).

### Definitions

Ventilator-associated pneumonia was diagnosed upon the presence of new and/or progressive pulmonary infiltrates on chest radiograph in a patient ventilated more than 48 h plus two or more of the following criteria: fever  $\geq 38.5^{\circ}\text{C}$  or hypothermia  $<36^{\circ}\text{C}$ , leukocytosis  $\geq 12 \times 10^9/\text{l}$ , purulent tracheobronchial secretions or a reduction of  $\text{PaO}_2/\text{FiO}_2 \geq 15\%$  in the last 48 h according to the Center for Disease Control (CDC) definitions [16]. We also included as pneumonia those with a clinical pulmonary infection score (CPIS) [17]  $\geq 6$ . Early-onset VAP was defined as occurring within the first 4 days of hospitalization and late-onset VAP as occurring in day 5 or later on [18]. The isolation of one or more microorganisms in significant bacterial count was required to confirm the diagnosis. The clinical, radiological, and microbiologic data for the diagnosis of VAP were systematically reviewed by an independent investigator.

We considered the isolation (at any concentration) of the following microorganisms as non-pathogenic: Viridans group streptococci, coagulase-negative *Staphylococcus*, *Neisseria* spp., *Corynebacterium* spp., and *Candida* spp., unless proven otherwise.

### Microbiological protocol

Sampling of the lower respiratory tract in cases suspected of VAP was performed by endotracheal aspiration (ETA) of respiratory secretions. For ETA, we obtained undiluted tracheal secretions. When aspiration was unproductive we irrigated with 2 ml of ringer lactate. Positive samples were considered as those with bacterial counts  $\geq 10^5$  cfu/ml of each significant microorganism. Occasionally, bronchoalveolar lavage samples or protected specimen brushes were obtained. In these cases, the cut-offs for positive samples were  $\geq 10^4$  and  $\geq 10^3$  cfu/ml, respectively.

All microorganisms were identified using standard methods, and antimicrobial susceptibility was determined according to clinical laboratory standard recommendations (CLSI) [19].

## Statistical analysis

Data were entered and categorized using Microsoft ACCESS®. For univariate analysis, continuous variables were assessed using the Mann–Whitney *U* test, and qualitative variables were studied with Fisher's exact test or  $\chi^2$  test. All statistical tests were two-tailed.

A multivariable logistic regression model was used to assess the independent value of predictor variables using SPSS software (SPSS Inc., Chicago, IL). For this analysis, quantitative variables were categorized establishing optimum cutoff thresholds selected from their ROC curves. A forward stepwise approach was followed, including as candidate variables all those that showed univariate significance better than  $P < 0.1$ . Results are presented as adjusted risk ratios with 95% confidence intervals. The models were validated by means of a jack-knifing technique [20]. Variables that yielded the same results in all the runs were qualified as "stable," while those variables that did not appear in at least 50% of the runs were discarded. No significant first-order interactions were found in the models.

From the final models we made an attempt to define predictive scores aiming to identify a subgroup of patients with higher risk of developing VAP. To this end we defined the scores as the addition of the significant variables weighted by their respective regression coefficients ( $\beta$ ). Two scores were studied: the day 0 score, including only variables available before surgery, and the day 3 score, selecting only patients who remained intubated >48 h and incorporating surgical and perisurgical data.

The aim of choosing these days was: (1) to create an early score to help the anesthetist in the decision of using or not a subglottic continuous aspiration tube before surgery (day 0 score) and (2) identify patients with a higher risk of VAP within the subset who remain intubated more than 48 h (day 3 score). In this latter score, only patients who remained ventilated on day 3 were included. Our objective was to study if a risk-stratified preventive approach was feasible or if universal prevention is the most advisable option. Finally, to assess the clinical relevance of the scores (beyond its statistical significance) we conducted a ROC analysis to determine the sensitivity/specificity achieved.

## Results

During the study period a total of 1,934 consecutive patients underwent MHS. Overall, 90 patients were excluded due to intraoperative or early postoperative (48 h) death, leaving a study population of 1,844 patients. Preoperative and surgical characteristics of the patients are shown in Table 1.

**Table 1** Preoperative and surgical characteristics of patients who underwent major heart surgery

Characteristics	Global
<b>Preoperative</b>	
No. of patients	1,844
Mean age in years (SD)	64.7 ± 12.5
Sex, male/female	1,058 (57.4)/786 (42.6)
Underlying conditions (%)	
Myocardial infarction (<90 days)	229 (12.4)
Congestive heart failure (Framingham criteria)	189 (10.2)
Central nervous system disorder	140 (7.6)
Chronic obstructive pulmonary disease(GOLD criteria)	205 (11.1)
Peripheral vascular disease	134 (7.3)
Gastrointestinal ulcer disease	98 (5.3)
Diabetes mellitus	437 (23.7)
Renal disease (creatinine ≥2 mg/dl)	133 (7.2)
Malignant neoplasm	48 (2.6)
Severe pulmonary hypertension (mPAP ≥60 mmHg)	196 (10.6)
Severe ventricular dysfunction (EF ≤ 30%)	153 (8.3)
Previous cardiac surgery (%)	185 (10.0)
New York Heart Association functional class (%)	
I	403 (21.8)
II	883 (47.9)
III	435 (23.6)
IV	123 (6.7)
EuroSCORE (%)	
Low risk (0–2)	160 (8.7)
Moderate risk (3–6)	815 (44.2)
High risk (>6)	869 (47.1)
<b>Surgical</b>	
Indication (%)	
Elective	1,699 (92.1)
Emergent	145 (7.9)
Type of surgery (%)	
Valvular replacement	971 (52.7)
Coronary artery bypass grafting (CABG)	393 (21.3)
Mixed (valvular and CABG)	176 (9.5)
Aortic surgery	129 (7.0)
Heart transplantation	61 (3.3)
Other	114 (6.2)
Mean cardiopulmonary bypass time (min) mean ± SD	112.6 ± 43.6
Mean aortic cross-clamp time (min) mean ± SD	74.4 ± 32.2

*EF* Ejection fraction, *GOLD* global initiative for chronic obstructive lung disease, *mPAP* mean pulmonary artery pressure

## Incidence and etiology of VAP

The cumulative incidence of VAP during the study period was 5.7% (106/1,844 patients). Of the 140 total episodes, 27 patients had more than 1 VAP episode. The incidence density of VAP in our population was 22.2 episodes per 1,000 days of mechanical ventilation. Mechanical ventilation >48 h was required by 231 patients (12.5%), and in this sub-group of patients VAP incidence was 45.9%.

**Table 2** Organisms isolated in patients with pneumonia

Organisms	Total episodes n = 140 (%)
<i>P. aeruginosa</i>	40 (28.6)
<i>S. aureus</i>	38 (27.1)
MRSA	25 (17.8)
MSSA	13 (9.3)
<i>H. influenzae</i>	24 (17.1)
<i>Enterobacter</i> spp.	16 (11.4)
<i>E. coli</i>	13 (9.3)
<i>Klebsiella</i> spp.	7 (5.0)
<i>Proteus</i> spp.	7 (5.0)
<i>S. maltophilia</i>	5 (3.6)
<i>Acinetobacter</i> spp.	4 (2.8)
<i>Serratia</i> spp.	3 (2.0)
<i>Moraxella</i> spp.	2 (1.4)
Polymicrobial	19 (13.5)

MRSA Methicillin-resistant *S. aureus*, MSSA methicillin-susceptible *S. aureus*

Tracheostomy was performed in 57 patients (3%), usually after 2 weeks of ventilation. These patients had 43 episodes of VAP (75.4%), which in 63% of cases occurred before tracheostomy. Overall, VAP was diagnosed after a median of 9 days of MV (IQR 5.7–24.0). Considering the day of hospital admission before surgery, only 4.7% (5/106) of our VAP cases could be considered as early onset (within  $\leq 4$  days of hospital stay).

There were significant differences in the incidence of VAP according to the type of surgery: valve replacement 4.6% (45/971), coronary artery bypass graft (CABG) 5.3% (21/393), mixed surgeries 10.2% (18/176), aortic surgery 8.5% (11/129), heart transplantation 3.3% (2/61), and other 7.9% (9/114) ( $P = 0.03$ ). Overall, 30 (1.6%) of the 1,844 patients presented sternal wound infections, 6 of which (20%) developed VAP.

Table 2 summarizes the microorganisms causing VAP in our study (140 episodes). Overall, 32.8% of VAP were caused by Enterobacteriaceae, 28.6% were caused by *Pseudomonas aeruginosa*, and 27.1% by *Staphylococcus aureus* (of them 65.8% were MRSA). VAP was polymicrobial in 13.5% of cases. All but 15 episodes had  $\geq 10^6$  cfu in the culture. These 15 patients usually had  $10^5$  cfu.

### Risk factors and predictive scores for VAP

Preoperative, operative and postoperative risk factors for development of VAP are shown in Table 3. As for the logistic regression model, the variables that yielded stable results in all the runs of the jack-knifing technique were: age  $>70$  (RR = 4.0), number of blood units transfused perioperatively (RR = 1.1 per unit), days of mechanical ventilation (RR = 1.1 per day), and reintubation (RR = 14.3). The variables that appeared as significant in

**Table 3** Univariate analysis of preoperative, operative and postoperative risk factors of VAP in patients underwent MHS

	Infection n = 106 (%)	No infection n = 1,738 (%)	RR (95% CI)	P value
<b>Preoperative risk factors</b>				
Age $>70$ years	73 (68.9)	730 (42.0)	3.1 (2.0–4.6)	$<0.001$
Intra-aortic balloon	6 (5.7)	40 (2.3)	2.6 (1.1–6.1)	0.04
Severe pulmonary hypertension	20 (18.9)	176 (10.1)	2.1 (1.2–3.4)	0.006
More than one previous heart surgery	25 (23.6)	160 (9.2)	3.0 (1.9–4.9)	$<0.001$
Peptic disease	15 (14.2)	83 (4.8)	3.3 (1.8–5.9)	$<0.001$
COPD	19 (17.9)	186 (10.7)	1.8 (1.1–3.1)	0.02
Diabetes	34 (32.1)	403 (23.2)	1.6 (1.0–2.4)	0.04
Peripheral vasculopathy	15 (14.2)	119 (6.8)	2.2 (1.3–4.0)	0.01
Neoplasia	9 (8.5)	39 (2.2)	4.0 (1.9–8.6)	0.001
Creatinine levels $>1.5$ mg/dl	19 (17.9)	114 (6.6)	3.1 (1.8–5.3)	$<0.001$
NYHA IV	20 (18.9)	103 (5.9)	3.7 (2.2–6.2)	$<0.001$
EuroScore, mean $\pm$ SD	9.2 $\pm$ 3.3	6.4 $\pm$ 3.2		$<0.001$
<b>Operative risk factors</b>				
Emergency	19 (17.9)	126 (7.2)	2.8 (1.6–4.7)	0.001
Intra-aortic balloon	19 (17.9)	70 (4.0)	5.2 (3.0–9.0)	$<0.001$
Perioperative myocardial infarction	9 (8.5)	38 (2.2)	4.2 (1.9–8.8)	0.001
Inotropic support	75 (70.8)	662 (38.1)	3.9 (2.6–6.0)	$<0.001$
CPBT, mean $\pm$ SD	137.8 $\pm$ 53.6	111.0 $\pm$ 42.4		$<0.001$
Mean aortic cross-clamp time $\pm$ SD	83.3 $\pm$ 44.7	73.2 $\pm$ 31.8		0.02
<b>Postoperative risk factors</b>				
Transfused units*, median (range)	9 (3–18)	2 (0–5)	4.9 (3.0–8.2)	$<0.001$
Reintervention	24 (22.6)	97 (5.6)		$<0.001$
Reintubation	65 (61.3)	67 (3.9)	39.5 (25–63)	$<0.001$
Days of MV median (IQR)	9 (5.7–24.0)	1.0 (1.0–1.0)		$<0.001$

COPD Chronic obstructive pulmonary disease, CPBT cardiopulmonary bypass time, MV mechanical ventilation, NYHA New York Heart Association functional class

\*Intraoperative and in the first 24 h



**Table 4** Multivariate analysis of risk factors for VAP in patients who underwent MHS

	RR (95% CI)	P
Age >70 years	4.0 (2.1–7.7)	<0.001
Number of transfused blood units	1.1 (1.04–1.1)	<0.001
Days on mechanical ventilation	1.1 (1.1–1.2)	<0.001
Reintubation	14.3 (7.9–25.8)	<0.001
Emergent surgery	42.5 (1.1–5.5)	0.02
Intraoperative inotropic support	2.1 (1.1–3.9)	0.01
Previous cardiac surgery	2.2 (1.1–4.5)	0.03

**Table 5** Independent predictive variables used to calculate the “day 0 VAP predictor score” and the “day 3 VAP predictor score”

Variable	Exp (β)	95% CI	P	Coefficient (β)	Standard error
Day 0 score					
NYHA IV	2.2	1.2–4.1	0.009	0.8	0.3
Age >70 years	3.5	2.2–5.5	<0.001	1.2	0.2
Previous cardiac surgery	3.0	1.8–5.0	<0.001	1.1	0.2
Emergent surgery	2.6	1.4–4.8	0.003	0.9	0.3
Peripheral vasculopathy	2.0	1.1–3.7	0.03	0.7	0.3
Previous neoplasia	3.4	1.5–7.5	0.003	1.2	0.4
Creatinine >1.5 mg/dl	2.3	1.3–4.0	0.004	0.8	0.3
Constant	0.01		<0.001	–4.1	0.2
Day 3 score					
Age > 70 years	3.3	1.9–5.9	<0.001	1.2	0.3
Constant	0.4		<0.001	–0.8	0.2

at least 50% of the jack-knifing runs were emergent surgery (RR = 2.5), intraoperative inotropic support (RR = 2.1), and previous cardiac surgery (RR = 2.2) (Table 4).

We developed two scores to help the clinicians to identify the subset of patients with a higher risk of developing VAP at two time points: before surgery, including all patients, and on day 3, including only patients who remained ventilated. Independent predictor variables at the operation day before intubation were: age >70 years (RR = 3.5), previous cardiac surgery (RR = 3), emergent surgery (RR = 2.6), NYHA IV (RR = 2.2), peripheral vasculopathy (RR = 2.0), previous neoplasia (RR = 3.4), and creatinine level >1.5 mg/dl (RR = 2.2) (Table 5). As their β coefficients were quite similar, we assigned 1 point to each variable. Results of the ROC analysis performed with the score values are presented in Fig. 1. As shown in the figure, a threshold value of ≥1 point shows a sensitivity of 93% and specificity of 40%; if the cutoff of ≥2 points is selected, the achieved sensitivity and specificity would be 51 and 84%, respectively.

For creating the second score (day 3 score), we selected the population who remained intubated at that time and included in the model all the preoperative and perioperative variables. The only independent predictor

for VAP identified in this population was: age >70 years (RR = 16.8). The sensitivity and specificity values obtained with this factor were 69.5 and 56%, respectively.

## Outcome

The median length of stay in the ICU was significantly longer in patients with VAP (25.5 days RIQ: 10–51.2) than in patients without VAP (3 days RIQ: 2–5) ( $P < 0.001$ ).

Overall in-hospital mortality in our study population was 6.9% (127/1,844), with a mortality rate in patients with VAP of 45.7 versus 2.8% in patients without VAP ( $P < 0.001$ ). Overall mortality of the 231 patients who required MV during more than 48 h was 43.7% (101) and was significantly higher in the subgroup who developed VAP (58/106; 54.7% vs. 43/125; 34.4%.  $P = 0.002$ ).


## Discussion

Our paper demonstrates a high incidence density of VAP in patients undergoing MHS and that most predictive risk factors are not amenable to intervention. The combination of the VAP predictive score and/or the need of ventilation for more than 48 h identify a population in such high-risk of VAP that, in our opinion, justifies the prospective study of preemptive measures.

Of the 1,844 patient evaluated, 231 (12.5%) remained ventilated more than 48 h. In this high-risk population, we detected 140 episodes of VAP in 106 patients, with an overall incidence of 45.9%. VAP was diagnosed in 75.4% of patients requiring tracheostomy. Patients mostly developed VAP before tracheostomy, which was usually performed 2 weeks after surgery. Some authors recommend early tracheostomy, but its impact is not clear in MHS patients. The overall incidence of VAP was of 5.7% (22.2 episodes per 1,000 days of mechanical ventilation). This incidence density of VAP, as well as the high number of patients on prolonged MV, reflects the complexity of the patients operated on in our center (47% in Euroscore’s high-risk category). In other series the incidence of VAP ranged from 7 to 40% [21–24], depending on age group, underlying condition, and other risk factors. Incidence is generally higher in surgical ICUs than in medical or mixed ones [6, 7]. We do not think that the use of the CPIS influenced our incidence, since it was only used as an adjunctive tool to establish the diagnosis and for early discontinuation of empiric treatment.

MHS patients usually have advanced age, severe underlying conditions, and a high rate of in-hospital instrumentation [7, 25]. Nosocomial infections are

**Fig. 1** Receiver operating characteristic (ROC) curve of day 0 score and coordinates of the curve showing the specificity, sensitivity, likelihood ratio for positive test (LR+), and likelihood ratio for negative test (LR-)



Coordinates of the ROC curve

Test Result Variable(s)	Positive if Greater Than or Equal To	Sensitivity (%)	Specificity (%)	LR+	LR-
Day zero score	0.5	93	40	1.55	0.17
	1.5	51	84	3.18	0.58
	2.5	20	97	6.66	0.82
	3.5	6	99	6.0	0.94
	4.5	1	99	1	1
	6	0	100		

common among this population, and VAP is the most frequent infectious disease [8, 11]. We believe the expertise of our cardiac catheterization team has made valvular replacement the most common type of surgery.

### Etiology

We have included in this series microbiologically confirmed VAPs, as suggested by the recent ATS recommendations. In the absence of a new antibiotic in the past 72 h, a sterile culture of respiratory secretions almost rules out the diagnosis of bacterial pneumonia. In most reports, *P. aeruginosa*, Enterobacteriaceae, and *S. aureus* are the three leading etiologies of VAP. Our study confirmed this data; 32.8% of VAP were caused by Enterobacteriaceae, 28.6% by *P. aeruginosa*, and 27.1% by *S. aureus*, of which 65.8% were MRSA.

MRSA is increasing in importance as a cause of VAP worldwide [26]. Risk factors for VAP caused by MRSA include COPD, longer duration of MV, prior antibiotic therapy, prior steroid treatment, and prior bronchoscopy [27, 28]. The risk of MRSA VAP is higher in endemic areas [28]. This is the case of our hospital, where MRSA represent almost 50% of all *S. aureus* infections.

### Risk factors

Our study of risk factors indicates that the variables independently related to VAP development (older age, previous cardiac surgery, previous neoplasia, cardiopulmonary bypass time, duration of VM, reintubation, blood transfusion) are hardly amenable to intervention when best-practice surgical, respiratory, and analgesic/sedation protocols are applied to prevent further complications.

The intubation process itself contributes to the risk of pneumonia [29]. Strategies aimed to reduce the days of ventilation, the rates of reintubation, or to promote non-invasive-ventilation (NIV) may decrease the risk for development of VAP [30–33]. A study has shown that the use of a pre-established protocol for respiratory care and sedation reduces the duration of MV and ICU stay [13].

Several studies in non-ICU patients have suggested that RBC transfusion increases the risk for nosocomial infection, including VAP. In a secondary analysis of data from a large study ( $n = 4,892$ ) of transfusion practices in critically ill patients, RBC transfusions were found to be an independent risk factor for VAP [34]. RBC transfusions may represent a partially modifiable risk factor, especially since a recent study by Levy et al. [35] has shown that patients receiving MV received transfusions at

higher pre-transfusion hemoglobin levels than patients not receiving MV ( $8.7 \pm 1.7$  vs.  $8.2 \pm 1.7$  g/dl, respectively;  $P < 0.001$ ), although the reason is not clear.

We developed a “day 0 score” to identify a population at high risk of pneumonia with the variables available before surgery. This idea derives from our recent demonstration in a prospective study of the protective value of continuous aspiration of subglottic secretions (CASS) in MHS patients [36]. The three-lumen tube required to perform CASS has a higher cost than the conventional endotracheal (two lumen) tube and would be desirable to select the subpopulation more likely to benefit of the triple lumen tube. Our score would accurately identify 93% of the patients who will develop pneumonia, with a specificity of 40%. Further studies are required to decide the cost efficacy of using CASS tubes for all or only part of the population.

The aim of the “day 3 score” was to identify patients at higher risk of developing pneumonia among those who remained ventilated  $>48$  h. These patients could be candidates for antimicrobial preventive measures. However, in our model the only independent predictor factor for VAP in this subgroup was age  $>70$  years. In the past, strategies employing prophylactic antibiotics have included selective digestive decontamination (SDD) [37, 38]. The mortality benefit of SDD appears to occur in surgical/trauma patients and to be associated primarily with the administration of parenteral antibiotics. Unfortunately, the application of SDD has been associated with the emergence of antibiotic-resistant bacterial strains, limiting its overall utility.

#### Impact on morbidity and mortality

The overall mortality rate of our series was 11.3%, almost exactly the EuroSCORE’s expected mortality (11.8%).

VAP mortality ranges from 20 to 70% in specific settings such as late-onset VAP or infections caused by high-risk pathogens [1, 18, 39, 40]. VAP also prolongs the duration of ventilation and ICU stay. In our study the median ICU length of stay for patients with and without VAP was, respectively, 25.5 and 3 days ( $P < 0.001$ ), and the mortality rate was, respectively, 45.7 and 2.8% in both populations ( $P < 0.001$ ).

Our study has some limitations. As our institution is a referral hospital, patient selection bias is present. In addition, although the normalization of blood glucose levels is a standard in our unit, we did not include it in the model. We tried to develop a VAP predictive score that could help clinicians to recognize especially high-risk patients; however, the relatively small sample size of our cohort (106 patients) may have contributed to its somewhat low sensitivity and specificity values.

In conclusion, we have found that, in patients undergoing MHS, the incidence density of VAP is high, and most predictive risk factors are not amenable to intervention. The combination of a risk score and/or the need of ventilation for more than 48 h identifies a population at such a high risk of VAP that, in our opinion, it justifies the prospective study of preemptive measures.

**Acknowledgments** We thank the staff of the microbiology laboratory and of the ICU for their enormous contribution to the study. This study was supported in part by a grant from the Spanish Social Security Health Investigation Fund (CIBER Enfermedades Respiratorias CB06/06/0058) Instituto de Salud Carlos III and by REIPI.

**Conflict of interest statement** The authors do not have any association that might pose a conflict of interest.

## References

1. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH (2002) Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. *Chest* 122:2115–2121
2. Bercault N, Boulain T (2001) Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. *Crit Care Med* 29:2303–2309
3. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C (1999) The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. *Am J Respir Crit Care Med* 159:1249–1256
4. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ (2003) Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. *Crit Care Med* 31:1312–1317
5. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C (1993) Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. *Am J Med* 94:281–288
6. Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, Rutala WA (1996) Risk factors for nosocomial pneumonia: comparing adult critical-care populations. *Am J Respir Crit Care Med* 153:158–162
7. Kollef MH (1993) Ventilator-associated pneumonia. A multivariate analysis. *Jama* 270:1965–1970
8. Kollef MH, Sharpless L, Vlasnik J, Pasque C, Murphy D, Fraser VJ (1997) The impact of nosocomial infections on patient outcomes following cardiac surgery. *Chest* 112:666–675
9. Sodano L, Agodi A, Barchitta M, Musumeci F, Menichetti A, Bellocchi P, Cunsolo R, Coco G (2004) Nosocomial infections in heart surgery patients: active surveillance in two Italian hospitals. *Ann Ig* 16:735–743

10. Bouza E, Hortal J, Munoz P, Pascau J, Perez MJ, Hiesmayr M (2006) Postoperative infections after major heart surgery and prevention of ventilator-associated pneumonia: a one-day European prevalence study (ESGNI-008). *J Hosp Infect* 64:224–230
11. Bouza E, Hortal J, Munoz P, Perez MJ, Riesgo MJ, Hiesmayr M (2006) Infections following major heart surgery in European intensive care units: there is room for improvement (ESGNI 007 Study). *J Hosp Infect* 63:399–405
12. Bouza E, Perez A, Munoz P, Jesus Perez M, Rincon C, Sanchez C, Martin-Rabadan P, Riesgo M (2003) Ventilator-associated pneumonia after heart surgery: a prospective analysis and the value of surveillance. *Crit Care Med* 31:1964–1970
13. Marelich GP, Murin S, Battistella F, Inciardi J, Vierra T, Roby M (2000) Protocol weaning of mechanical ventilation in medical and surgical patients by respiratory care practitioners and nurses: effect on weaning time and incidence of ventilator-associated pneumonia. *Chest* 118:459–467
14. Kress JP, Pohlman AS, O'Connor MF, Hall JB (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med* 342:1471–1477
15. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R (1999) European system for cardiac operative risk evaluation (EuroSCORE). *Eur J Cardiothorac Surg* 16:9–13
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 16:128–140
17. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM (1991) Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. *Am Rev Respir Dis* 143:1121–1129
18. American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 171:388–416
19. Institute CaLS (2005) Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI/NCCLS M100–S15. Clinical and Laboratory Standards Institute, Wayne
20. Ang RP (1998) Use of the Jackknife statistic to evaluate result replicability. *J Gen Psychol* 125:218–228
21. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C (1989) Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. *Am Rev Respir Dis* 139:877–884
22. Ibrahim EH, Mehringer L, Prentice D, Sherman G, Schaiff R, Fraser V, Kollef MH (2002) Early versus late enteral feeding of mechanically ventilated patients: results of a clinical trial. *JPEN J Parenter Enteral Nutr* 26:174–181
23. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V (1997) Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 156:1040–1048
24. Sirvent JM, Torres A, El-Ebiary M, Castro P, de Batlle J, Bonet A (1997) Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. *Am J Respir Crit Care Med* 155:1729–1734
25. Beck-Sague CM, Sinkowitz RL, Chinn RY, Vargo J, Kaler W, Jarvis WR (1996) Risk factors for ventilator-associated pneumonia in surgical intensive-care-unit patients. *Infect Control Hosp Epidemiol* 17:374–376
26. Richards MJ, Edwards JR, Culver DH, Gaynes RP (1999) Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. *Crit Care Med* 27:887–892
27. Pujol M, Corbella X, Pena C, Pallares R, Dorca J, Verdaguer R, Diaz-Prieto A, Ariza J, Gudiol F (1998) Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant *Staphylococcus aureus* pneumonia. *Eur J Clin Microbiol Infect Dis* 17:622–628
28. Rello J, Torres A, Ricart M, Valles J, Gonzalez J, Artigas A, Rodriguez-Roisin R (1994) Ventilator-associated pneumonia by *Staphylococcus aureus*. Comparison of methicillin-resistant and methicillin-sensitive episodes. *Am J Respir Crit Care Med* 150:1545–1549
29. Torres A, Gatell JM, Aznar E, el-Ebiary M, de la Puig Bellacasa J, Gonzalez J, Ferrer M, Rodriguez-Roisin R (1995) Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. *Am J Respir Crit Care Med* 152:137–141
30. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, Gasparetto A, Lemaire F et al (1995) Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 333:817–822
31. Antonelli M, Conti G, Rocco M, Bufi M, De Blasi RA, Vivino G, Gasparetto A, Meduri GU (1998) A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 339:429–435
32. Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G, Dupon M, Reiffers J, Cardinaud JP (2001) Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. *N Engl J Med* 344:481–487
33. Antonelli M, Conti G, Esquinas A, Montini L, Maggiore SM, Bello G, Rocco M, Maviglia R, Pennisi MA, Gonzalez-Diaz G, Meduri GU (2007) A multiple-center survey on the use in clinical practice of noninvasive ventilation as a first-line intervention for acute respiratory distress syndrome. *Crit Care Med* 35:18–25
34. Shorr AF, Duh MS, Kelly KM, Kollef MH (2004) Red blood cell transfusion and ventilator-associated pneumonia: a potential link? *Crit Care Med* 32:666–674
35. Levy JH, Tanaka KA, Steiner ME (2005) Evaluation and management of bleeding during cardiac surgery. *Curr Hematol Rep* 4:368–372
36. Bouza E, Pérez MJ, Muñoz P, Rincón C, Barrio JM, Hortal J (2008) Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery. *Chest* 134:938–946
37. Kollef MH (2000) Opinion: the clinical use of selective digestive decontamination. *Crit Care* 4:327–332
38. Kollef MH (2003) Selective digestive decontamination should not be routinely employed. *Chest* 123:464S–468S
39. Valles J, Pobo A, Garcia-Esquirol O, Mariscal D, Real J, Fernandez R (2007) Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset. *Intensive Care Med* 33:1363–1368
40. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. *Am J Respir Crit Care Med* 165:867–903